PBM promises a pathway to lower-cost drugs

14 November 2018

The USA’s leading pharmacy benefit manager (PBM) has announced that it is introducing a new formulary to provide employers and health plans a better opportunity to leverage changing dynamics to help lower their members' out-of-pocket costs.

PBMs are currently keen to show what action they are taking to bring down drug costs for patients amid criticism of their role – as well as of the high list prices set by pharma companies – in driving up the expense of medicines in the USA.

The Express Scripts (Nasdaq: ESRX) National Preferred Flex Formulary, which the group claims is built for the ‘evolution of drug pricing’, will come into being on January 1, 2019.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK